Clinical trial NCT06637163: Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Official title: A Randomized Controlled, Multicenter Clinical Study of Benmelstobart Combined With Radiochemotherapy Versus Radiochemotherapy as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Esophageal Squamous Cell Carcinoma
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2024-10-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will explore the efficacy and safety of benmelstobart combined with radiochemotherapy compared to radiochemotherapy alone as neoadjuvant treatment for esophageal squamous cell carcinoma. It will also compare the effectiveness and safety of low-dose radiotherapy versus standard-dose radiotherapy in neoadjuvant regimens that include benmelstobart with concurrent radiochemotherapy. This research may provide more treatment options for patients with esophageal squamous cell carcinoma.

Detailed description: Eligible participants will be randomly assigned in a 1:1 ratio to either the benmelstobart plus radiochemotherapy group or the radiochemotherapy group. Surgery will be performed 6-8 weeks after the completion of neoadjuvant treatment, with the primary endpoint being the rate of pathological complete response (pCR).

Eligibility criteria: Inclusion Criteria:

* Patients voluntarily participate in this study and sign informed consent forms, with good compliance.
* Aged 18 years and older, regardless of gender.
* ECOG performance status: 0-1.
* Patients with histologically confirmed clinical stages T1-3N+M0 or T3NanyM0 of resectable esophageal squamous cell carcinoma.
* No prior antitumor treatment for esophageal cancer, including chemotherapy, hormone therapy, radiotherapy, or immunotherapy.
* Laboratory tests must meet the following criteria (within 7 days prior to baseline enrollment):

  1. Complete blood count: a. Hemoglobin (Hb) ≥ 90 g/L (no blood transfusion in the last 14 days); b. Neutrophil count (NEUT) ≥ 1.5 × 10\^9/L; c. Platelet count (PLT) ≥ 100 × 10\^9/L; d. White blood cell count (WBC) ≥ 3 × 10\^9/L;
  2. Biochemical tests: a. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; b. Total bilirubin (TBIL) ≤ 1.5 × ULN; c. Serum creatinine (Cr) ≤ 1.5 × ULN (or creatinine clearance (CCr) ≥ 60 mL/min);
  3. Coagulation function: activated partial thromboplastin time (APTT), International normalized ratio (INR), prothrombin time (PT) ≤ 1.5 × ULN;
  4. Thyroid function: Thyroid-stimulating hormone (TSH) ≤ ULN (if abnormal, FT3 and FT4 levels should also be assessed; if FT3 and FT4 levels are normal, the patient can be enrolled);
  5. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ 50%;
* Female participants must agree to use contraception (e.g., intrauterine device \[IUD\], contraceptive pills, or condoms) during the study and for 6 months after the study ends; a negative serum pregnancy test must be obtained within 7 days prior to enrollment, and participants must not be breastfeeding. Male participants must also agree to use contraception during the study and for 6 months after the study ends.

Exclusion Criteria:

Participants with any of the following criteria will be excluded from the study:

* Presence of other malignant tumors (except for previously cured basal cell carcinoma of the skin).
* Diagnosis of cervical esophageal cancer.
* Severe hypersensitivity reactions following the administration of other monoclonal antibodies.
* Any active autoimmune disease or history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; asthma requiring bronchodilator intervention). However, patients with the following conditions may be included: vitiligo, psoriasis, alopecia that do not require systemic treatment, well-controlled type 1 diabetes, and hypothyroidism with normal thyroid function under replacement therapy.
* Use of immunosuppressants, systemic, or absorbable local hormone therapy to achieve immunosuppressive effects (doses \> 10 mg/day of prednisone or equivalent), and continuing use within 2 weeks of the first dose.
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
* Uncontrollable neurological symptoms from brain metastases, spinal cord compression, or carcinomatous meningitis occurring within 4 weeks prior to the first dose, or evidence of brain or leptomeningeal disease found on CT or MRI screening.
* Presence of any severe and/or uncontrolled disease, including:

  1. Acute or persistent myocardial ischemia or myocardial infarction, poorly controlled clinically significant arrhythmias, and NYHA class II or higher heart failure; LVEF \< 50%.
  2. Active or uncontrolled severe infections (≥ CTCAE grade 2 infections).
* Vaccination with preventive or attenuated vaccines within 4 weeks prior to the first dose.
* Any factors, as judged by the investigator, that could lead to premature termination of the study, such as other serious illnesses (including mental illness) requiring concurrent treatment, significant laboratory abnormalities, or family or social factors that could affect participant safety.
* For participants who are HBsAg (+) and/or HBcAb (+), HBV DNA must be \< 500 IU/mL (if the local center's lower limit of detection is higher than 500 IU/mL, the investigator may decide on enrollment based on specific circumstances) and must continue to receive effective anti-HBV treatment during the study, or must have initiated treatment with entecavir or tenofovir prior to the study drug.
* For participants who are HCV antibody positive, HCV-RNA testing is required; those with HCV-RNA \> 10\^3 copies/mL will be excluded.
* Positive HIV test.

Primary outcomes:
measure: Pathological complete response (pCR)
timeFrame: 4 months
Secondary outcomes:
measure: Major pathologic response (MPR)
timeFrame: 4 months
measure: Overall response rate (ORR)
timeFrame: 4 months
measure: Diseases control rate (DCR)
timeFrame: 4 months
measure: R0 resection rate
timeFrame: 4 months
measure: Disease free survival (DFS), 1y-DFS
timeFrame: 15 months
measure: Overall survival (OS), 1y-OS
timeFrame: 15 months
measure: Surgical-related Indicators
timeFrame: 1 months
measure: Neoadjuvant Treatment Completion Rate
timeFrame: 1 months
measure: Adverse events
timeFrame: 15 months
Other outcomes:
Locations:
city: Shantou
country: China
facility: Cancer Hospital of Shantou University Medical College
state: Guangdong
city: Shenyang
country: China
facility: Liaoning Cancer Hospital and Institute
state: Liaoning
city: Shanghai
country: China
facility: Zhongshan Hospital Fudan University
state: Shanghai
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital
state: Tianjin
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
state: Zhejiang
Study officials:
affiliation: Fudan University
name: Lijie Tan, Professor
role: PRINCIPAL_INVESTIGATOR
References: